Uncategorized

CAR-T Therapy: Challenges for implementation in Canada

CAR-T Therapy: Challenges for implementation in Canada In 2017, autologous chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel (Kymriah®, Novartis), became the first gene therapy approved in the United States for acute lymphoblastic leukaemia in children and young adults. In 2018, regulatory approval in the UK and Canada followed suit, approving Kymriah® for some patients with […]

Read More

Real-World Evidence (RWE) and Health Technology Assessment (HTA) Decision-Making

Interest is intensifying across the globe for utilizing real-world evidence (RWE) to inform decision-making by reimbursement organizations. For instance, the Canadian Agency for Drugs and Technologies in Health (CADTH) have noted: All evidence is considered for health technology assessment (HTA) submissions Data derived outside the confines of a randomized controlled trial (RCT) can be particularly […]

Read More